857532-23-1

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-(4-broMophenyl)-4-(4-chlorophenyl)-, 1,1-diMethylethyl ester
• Synonyms: 1-Piperidinecarboxylic acid, 4-(4-broMophenyl)-4-(4-chlorophenyl)-, 1,1-diMethylethyl ester;tert-butyl 4-(4-broMophenyl)-4-(4-chlorophenyl)piperidine-1-carboxylate
• CAS NO: 857532-23-1
• Molecular Formula: C₂₂H₂₅BrClNO₂
• Molecular Weight: 450.7964
• Mol File: 857532-23-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 496.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.327±0.06 g/cm3(Predicted)
• PKA: -2.23±0.40(Predicted)
• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-(4-broMophenyl)-4-(4-chlorophenyl)-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-(4-broMophenyl)-4-(4-chlorophenyl)-, 1,1-diMethylethyl ester(857532-23-1)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-(4-broMophenyl)-4-(4-chlorophenyl)-, 1,1-diMethylethyl ester(857532-23-1)

Safety Data

• Hazardous Substances Data: 857532-23-1(Hazardous Substances Data)

Usage

Molecular structure

A complex structure derived from piperidinecarboxylic acid.

Ester form

Potential candidate for use in pharmaceuticals or research applications.

Bromophenyl and chlorophenyl groups

Suggest potential in the field of medicinal chemistry.

1,1-Dimethylethyl ester group

Makes the molecule lipophilic, potentially increasing bioavailability and cellular uptake.

Further research needed

To determine specific applications and potential biological activities.

Upstream product

• 57988-58-6 4-(4-bromophenyl)-4-hydroxy-piperidine 
• 108-90-7 chlorobenzene 
• 857531-97-6 4-(4-bromophenyl)-4-(4-chlorophenyl)-piperidine hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 857531-01-2 4-(4-bromo-phenyl)-4-(4-chloro-phenyl)-piperidine 

Downstream Products

• 885595-12-0 4-(1-(tert-butoxycarbonyl)-4-(4-chlorophenyl)piperidin-4-yl)phenylboronic acid 
• 857532-22-0 4-(4-carboxy-phenyl)-4-(4-chloro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 885595-15-3 tert-butyl 4-(4-chlorophenyl)-4-(4-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)phenyl)piperidine-1-carboxylate 
• 917899-37-7 4-(4-chloro-phenyl)-4-[4-(1-dimethylsulphamoyl-5-ethyl-1H-pyrazol-4-yl)-phenyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1057384-12-9 C₂₈H₂₈ClN₃O₂S 
• 917899-36-6 tert-butyl 4-(4-chlorophenyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine-1-carboxylate 

Relevant articles and documents

5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS

Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I).

PHARMACEUTICAL COMPOUNDS

Compounds of the formula (I), and salts, solvates, tautomers and N-oxide thereof; wherein TG is selected from groups (1) and (2): wherein the asterisk (*) represents the point of attachment of the group E to the group X; Rla is an optionally substituted aryl or heteroaryl group; Rlb is hydrogen or a group Rla; X is an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 are heteroatoms selected from O, N and S; and A, E, R2, R3, R4, Q1 and Q2 are as defined in the claims; provided that when E is aryl or heteroaryl, then Q2 is other than a bond; and further provided that the moiety (a) is other than a group (BG1) or (BG2); wherein (BGl) and (BG2) are each optionally substituted; T is N or CRZ; J1-J2 is selected from N=C(RZ), (RZ)C=N, (RZ)N-C(O), (RZ)2C-C(O), N=N and (RZ)C=C(R6); J4 -J3 is a group N=C(RZ) or a group (RZ)N-CO; and RZ is hydrogen or a substituent. The compounds of the formula (I) have PKA and PKB kinase inhibiting activity and are useful in the treatment of cancers.

HETEROCYCLIC CONTAINING AMINES AS KINASE B INHIBITORS

The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof; for use as a PKB kinase inhibitor or PKA kinase inhibitor. In formula (I), A is a saturated hydrocarbon linker group; E is a monocyclic or bicyclic carbo